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Objectives: Long-term clinical follow-up of new drug-eluting stents is essential to
ensure continued safety in patients treated with these DES in clinical practice. Two
clinical trials of the MiStent SES are currently in long-term follow-up; the DES-
SOLVE I clinical trial, a ﬁrst-in-human study of 30 patients conducted at 5 sites
evaluating the MiStent SES, and the DESSOLVE II clinical trial, a 2:1 randomized
study of 184 patients conducted at 26 sites evaluating the MiStent SES as compared to
the control stent, the Endeavor Sprint.
Methods: The MiStent SES uses a unique combination of a crystalline formu-
lation of sirolimus and a rapid, fully absorbable polymer on a thin-strut, cobalt
chromium stent platform. The polymer coating is eliminated from the stent in
45-60 days with complete tissue absorption within 90 days; however, uniquely,
the crystalline sirolimus continues to maintain therapeutic tissue levels of siro-
limus up to 9 months. In the trials, patients with discrete de novo lesions up to
27 mm in length in native coronary arteries were enrolled. The primary endpoint
of in-stent late lumen loss (LLL) was evaluated in both trials. Patients were also
followed for clinical events at predeﬁned intervals. MACE was deﬁned as all
death, Q and non-Q wave myocardial infarction and all target vessel
revascularization.
Results: The DESSOLVE I trial demonstrated minimal progression of late lumen loss
between 8 and 18 months follow-up (0.090.10 and 0.090.15) respectively, with no
target lesion MACE events through 3 years. In the DESSOLVE II trial, the MiStent
LLL was superior to the Endeavor LLL (0.270.46 versus 0.580.41). MACE for
MiStent SES and Endeavor was 4.3% versus 6.7% (P¼0.49) respectively at 9 months,
5.1% versus 8.3% (P¼0.51) at 12 months, and 6.7% versus 13.3% (P¼0.167) at
2 years. Evaluation of imaging (angiographic, IVUS, OCT) at various time points and
clinical outcomes of the MiStent SES for DESSOLVE I and DESSOLVE II to 3 years
will be presented.
Conclusions: The MiStent SES is a unique DES combining short-term polymer
exposure of 3 months with a long-term sirolimus elution proﬁle of 9 months. These
studies verify the efﬁcacy of the MiStent SES with a sustained safety proﬁle.
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Preventive effects of cordyceps sinensis against contrast induced nephropathy
in type 2 diabetics with renal insufﬁciency undergoing coronary angiography
Zhao Kai, Gao Sheng, Li Yongjian, Zhang Boya, Lin Yu, Jin Zhe, Zhao Kai
Department of Cardiology, Tianjin Nankai Hospital
Objectives: To study the preventive effects of cordyceps sinensis (CS) against
contrast induced nephropathy (CIN) in type 2 diabetics with renal insufﬁciency un-
dergoing coronary angiography.
Methods: A total of 210 patients with type 2 diabetes and estimated glomerular
ﬁltration rate (eGFR) of 60ml/min/1.73m2 or less, were randomly divided into three
groups, basic treatment group (n¼71), standard CS therapy group (n¼69, corbrin
capsule 2g, 3 times/d were used 3 days before and after angiography), and intensive
CS therapy group (n¼70, corbrin capsule 3g, 3 times/d were used 3 days before and
after angiography). Serum creatinine (Scr) and eGFR were assessed at the time of
hospital admission and on days 1, 2, and 3 after angiography. The values of urine
neutrophil-gelatinase-associate-lipocalin (NGAL), kidney injury molecule-1 (KIM-1),
and interleukin-18 (IL-18) were detected before angiography and 1 day after angi-
ography in the patients of three groups. The primary end point was the prevalence of
CIN. The secondary end point was a 25% or greater reduction in eGFR.
Results: CIN occurred in 19 of 210 patients (9.04%). The prevalence of CIN was
lower in the CS treatment groups than in the basic treatment group (P<0.05), and
a signiﬁcant decrease in the prevalence of CIN in the intensive CS therapy group
was shown (P<0.01). Compared with the basic treatment group, a lower pro-
portion of patients in the CS treatment groups had an eGFR decrease of 25% or
greater (P<0.05) ; patients with an eGFR decrease of 25% or greater accounted
for even lower proportion in the intensive CS therapy group and a statistical
signiﬁcance was reached (P<0.01). Within 1 day after the procedure, urine
levels of KIM-1, NGAL, and IL-18 in patients in the intensive CS therapy
group were lower than those in the basic treatment group and standard therapy
group (P<0.05). Multiple Logistic Regression showed that advanced age, lower
eGFR levels, and higher dose of contrast volume were independent risk factors
of CIN.
Conclusions: CS is a protective factor against CIN in type 2 diabetics with renal
insufﬁciency undergoing coronary angiography and intensive CS therapy could be
more effective.C138 JACC Vol 64/16/Suppl C j October 16–1GW25-e0278
Coronary Flow Reserve in the Remote Myocardium Predict Left Ventricular
Remodeling Following Acute Myocardial Infarction
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Objectives: The objective of the present study was to assess whether a relationship
exists between CFR in the non-infarcted myocardium and left ventricular remodeling
following AMI.
Methods:We enrolled 42 consecutive patients undergoing PCI. All patients were
subjected to two-dimensional echocardiography (2-DE) and real-time myocardial
contrast echocardiography (RT-MCE) to assess left ventricular function and CFR
one week following PCI. RT-MCE was performed both at rest and during
dobutamine infusion to assess CFR in the infarcted myocardium and non-
infarcted myocardium. After six months, 2-DE was repeated to reassess left
ventricular function. The remodeling was deﬁned as an increase in LVEDV by at
least more than 20%. Twenty subjects were enrolled as the control group and
were examined using the same method to assess CFR. cTnI levels were routinely
analyzed on admission as a serum speciﬁc marker of myonecrosis and repeated
every six hours during the ﬁrst 24 hours post-PCI in order to estimate peak
concentration.
Results: Compared with the infarcted myocardium and non-infarcted myocar-
dium, both at baseline and following low dose dobutamine administration,
myocardial blood ﬂow (MBF) in the non-infarcted myocardium was signiﬁcantly
higher than in the infarcted myocardium, and mean CFR of the non-infarcted
myocardium was also signiﬁcantly higher than observed in the infarcted
myocardium (2.650.31 vs.2.130.25, P<0.01). There was no difference
observed in MBF between the non-infarcted myocardium and normal myocar-
dium at baseline, while at peak stress, MBF in the normal myocardium was
signiﬁcantly increased than that in the non-infarcted myocardium (11.21.11 vs.
8.982.53 dB/s, P<0.05). Mean CFR was also higher compared to the non-
infarcted myocardium (3.080.29 vs. 2.650.31, P<0.01). According to CFR
cut-off value of 2.39 in the non-infarcted myocardium as providing the maximal
accuracy to distinguish between patients with impaired CFR and preserved CFR,
all patients were divided into two subgroups: Group I (CFR<2.39) and Group II
(CFR2.39). The levels of cTnI were higher in Group I compared to Group II
on admission (36.40 vs.21.38mg/ml, P<0.05). Furthermore, at six months
following coronary angioplasty, LVEDV and LVESV in Group I were increased
(132 vs. 137 ml, and 69 vs. 76 ml, respectively), and lLVFF was decreased
(47% vs. 45%). In Group II, LVEDV and LVESV was decreased (131 vs. 128
ml, and 68 vs. 59 ml, respectively), while LVEF was increased (48% vs. 53%).
There are nine patients with remodeling in Group I while only two in Group II.
Furthermore, we analyzed the correlation between CFR in the non-infarcted
myocardium and parameters of LV function. There was a signiﬁcant negative
correlation between CFR and LVEDV, LVESV in the non-infarcted myocardium
(r¼-0.623, P<0.001, r¼-0.696, P<0.001, respectively). LVEF and CFR in the
non-infarcted myocardium were also correlated with each other (r¼0.658,
P<0.001).
Conclusions: Microvascular dysfunction is commonly observed in the non-infarcted
myocardium. The CFR value in the non-infarcted myocardium accurately predicts
adverse left ventricular remodeling following AMI.GW25-e1117
Rotational Atherectomy Combined with Cutting Balloon for the Treatment of
Severely Calciﬁed Coronary Lesions: An Intravascular Ultrasound Study
Tang Zhe, Bai Jing, Wang Yu
Chinese PLA General Hospital
Objectives: The intravascular ultrasound (IVUS) study was designed to evaluate the
immediate efﬁcacy and safety of rotational atherectomy combined with cutting
balloon for severely calciﬁed coronary lesions.
Methods: Eighty consecutive patients with severely calciﬁed coronary lesions which
were deﬁned by coronary angiography and IVUS (calcium arc180, calcium length
ratio0.5) and deposed by rotational atherectomy were divided into 2 groups. There
were 34 in rotational atherectomy (RA) group and 46 in rotational atherectomy
combined with cutting balloon (RC) group. In all lesions, we used RA to ﬁrst depose
the stenosis. In RC group, after RA, we used cutting balloon for the future plaque
modiﬁcation. The size of RA bur and cutting balloon are recorded.IVUS was per-
formed before percutaneous coronary intervention (PCI) to measured lumen cross-
sectional area (CSA), external elastic membrane (EEM), Plaque and media CSA ¼
EEM CSA-lumen CSA. Lumen CSA of every 1 mm of culprit lesion segment was
measured and average lumen CSA was calculated. For calcium, we measured
maximum calcium arc, calcium length, and calcium ratio (calcium length/lesion
length). After stent implantation, IVUS was rechecked to measure minimum stent
CSA, minimum and maximum stent diameter, and the reference lumen CSA. Stent
symmetry ¼ minimum stent diameter/maximum stent diameter. Stent expansion ¼
minimum stent CSA/reference lumen CSA. Incomplete stent apposition was deﬁned
as insufﬁciently close contact between some struts and the underlying wall. What’s9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
